ICER goes after Novartis for overpricing MS drug; Valneva, GlaxoSmithKline breaks vaccine pact
→ ICER is coming out against the price of Novartis’ Mayzent (siponimod), arguing the multiple sclerosis treatment has a low long-term value for money. While the price watchdog acknowledges there’s some evidence that the drug — a blockbuster-to-be priced at $88,000 a year — can improve outcomes for patients with active secondary progressive MS, it’s dissatisfied with its lack of benefit for the whole population tested in a Phase III (Notably, the FDA approval covers a slightly different group, namely relapsed/refractory MS). Their advice to payers: “Given its similarities to fingolimod, siponimod should be considered amongst a group of highly effective disease modifying therapies (DMTs) for relapsing forms of MS, including fingolimod, alemtuzumab, natalizumab, and ocrelizumab.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.